New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
06:56 EDTACHNAchillion reports interim results on ACH-3102
Achillion announced that it has completed enrollment in a pilot Phase 2a trial evaluating ACH-3102, a second-generation pan-genotypic NS5A inhibitor, in combination with ribavirin for the treatment of patients with chronic genotype 1b hepatitis C virus infection. Up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic breakthrough observed to date.
News For ACHN From The Last 14 Days
Check below for free stories on ACHN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
10:50 EDTACHNAchillion call activity attributed to takeover speculation
Achillion August7 and 8 calls are active on total call volume of 2,800 contracts (140 puts) on takeover speculation. August call option implied volatility is at 137, September is at 129, December is at 131; compared to its 26-week average of 113 according to Track Data. Active call volume suggests traders taking positions for large price movement.
10:39 EDTACHNRumor: Achillion strength attributed to takeover speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use